Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer

Yonsei University

Status: Unknown

Conditions: Stomach Neoplasms

Study type: Observational

Funder types: Other

Identifiers

NCT02136836

GSCH-STO13-01

Roche (Other Identifier)

Details and patient eligibility

About

The objective of this study is to investigate the proportion of HER2 overexpression in gastric cancer patients group, to evaluate the relation of HER2 overexpression with prognosis, and to analyze the proportion of herceptin applied to patients in clinical field. Furthermore, the investigators are going to reevaluate the clinical benefit of Herceptin for survival prolongation compared to chemotherapy only.

Enrollment: 860 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Histologically confirmed gastric adenocarcinoma
2. Patients were diagnosed during 2006-2013
3. HER2 expression status was evaluated in primary gastric cancer or metastatic lesion.

Exclusion criteria

• Patients with second primary cancer within 5 years

Trial design

860 participants in 1 patient group

gastric adenocarcinoma